

Total Heart Intelligence… Wherever You Are

THIRD QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL

NOVEMBER 12, 2026

NASDAQ: BEAT

Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, regulatory and clinical timelines, reimbursement and commercialization plans, business strategy and plans and objectives of management for future operations, are forward-looking statements.

These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "aims," "predicts," "potential," "seeks," "attempts," "poised" or "continues" or the negative of these terms or other similar words. These statements are only predictions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness.

In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see disclosures contained in HeartBeam's public filings with the SEC, including the "Risk Factors" in HeartBeam's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which may be viewed at www.sec.gov.

The HeartBeam System received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. The HeartBeam System is FDA-cleared for arrhythmia assessment only; its use for heart attack assessment is investigational and not FDA cleared. Breakthrough Device Designation and acceptance into the TAP Pilot do not change regulatory requirements and do not guarantee FDA authorization or coverage. Refer to the Company's Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

Agenda

WHAT WE'LL COVER

1. Progress on Key Strategic Priorities
2. HeartBeam's Cardiac Platform Opportunity
3. Heart Attack Detection: Significant Milestones Achieved
4. Financials

ON THE CALL TODAY



RICHARD FERRARI

Executive Chairman



DR. BRANISLAV VAJDIC

President & Founder



TIM CRUICKSHANK

Chief Financial Officer

Progress on Key Strategic Priorities

Heart Attack Detection is our top strategic priority. Clinical and Regulatory initiatives are rapidly advancing.

HEART ATTACK DETECTION

- Significant milestones achieved with BDD, TAP Pilot enrollment, and ALIGN-ACS pilot study
- Shortened path to FDA Clearance
- Alignment with FDA on 510(k) Pathway
- Actively finalizing U.S. Pivotal Study design with FDA

UNLOCKING PAYMENT PATHWAYS

- Building supporting data for symptom-to-door time
- Creating real-world evidence and assessing coding, coverage and payment pathways
- Expanding efforts with reimbursement experts

LONG-TERM VALUE & AI

- $40B+ cardiac platform opportunity
- Multiple form factors
- Information-rich 3D signal goes beyond current ECG wearables and is a differentiated foundation for AI processing

FINANCIALS & COST PROFILE

- Created capital efficiency through focused path to Heart Attack Detection
- Q3 cash outflows of $2.6M down 23% vs. Q2, ahead of schedule
- Pro forma cash of $10.1M extends the cash runway in line with key milestones

HeartBeam System is FDA-cleared for arrhythmia assessment only. Heart attack detection and AI algorithm are investigational, not cleared by FDA and not available for sale in the United States or other geographies. Pro forma cash is unaudited and reflects approximately $4.0M raised under the ATM in Q4 2026.

HeartBeam's Cardiac Platform Opportunity

Patient Delay is the Major Driver Behind the **#1 Cause of Death**

Treatment time in hospital is optimized. Patient delay happens before arrival.



SYMPTOM-TO-DOOR

Patients Delay 2+ Hours Before Taking Action[1]

Uncertainty Delays Action

PATIENT OUTCOME

Every **30 Minute** Delay Increases[1]:

8.7% ▲ Heart failure risk

7.5% ▲ 1-year mortality

COSTLY COMPLICATIONS

Heart failure drives:

$30,000 annual cost per patient[2]

5-year avg. life expectancy[3]

Decison to call 911

DOOR-TO-BALLOON

Treatment Time is Optimized Once the Patient Reaches the Hospital

Rapid 12-Lead ECG in guidelines



Rapid EMS activation and transport



Streamlined emergency room triage



Immediate stenting with door-to-balloon time under 90 min

There is no dependable solution to reduce this pre-hospital delay.

Current at-home ECG tools cannot reliably detect heart attacks.

[1] De Luca G. Circulation. 2004 Mar 16;109(10):1223-5. [2] Heidenreich PA, J Card Fail. 2022 Mar;28(3):453-466. [3] Heart Failure Society of America, Heart Failure Facts & Information.

Data shown reflects the burden of heart attack, not general cardiovascular disease. Heart Attack Detection product not cleared by FDA and not available for sale in the United States or other geographies.

HeartBeam's Core Technology and Platform

Why HeartBeam Is Fundamentally Different

Cardiac Platform Opportunity

- Closes the gap between symptom onset and care by giving patients a clinical grade ECG wherever they are, at the moment symptoms occur.
- First-of-its-kind, portable, cable-free ECG device recorded by a patient.
- Clinical-grade product read by a physician vs. current market of consumer products read by a patient.

Built for What's Next

- Powered by 25+ issued patents worldwide incorporating our proprietary technology.
- The same signal architecture that powers our card today also powers our Patch and HeartBeam Remote unit.

CARDIAC PLATFORM OPPORTUNITY[i]

$40B

Ability to serve 50M+ patients across multiple applications and form factors

HEART ATTACK RISK[ii]

20M+

Adults in the U.S. at risk of Heart Attack


i. 260+ million adults in U.S. × ~20% either rhythm diagnosis, palpitations, or recurring unexplained cardiac symptoms reported at some point × $750 per year per patient

ii. 20+ million patients in U.S. at risk of heart attack (8 million prior MI + 12 million at high risk)

Ischemia, AI algorithm, 12-Lead patch and HeartBeam Remote products not cleared by FDA and not available for sale in the United States or other geographies.

One platform. Multiple form factors.
Shared cardiac intelligence.

CORE PLATFORM



PATENTED 3D 3L SIGNAL
COLLECTION TECHNOLOGY

FORM FACTORS

HEARTBEAM SYSTEM*
CABLE-FREE 12-LEAD ECG FOR AT-HOME USE



12-LEAD PATCH
CONTINUOUS 1-LEAD → 12-LEAD ON DEMAND



HEARTBEAM REMOTE UNIT
PRIMARY APPLICATION OUTSIDE THE US



APPLICATIONS ENABLED

ARRHYTHMIA ASSESSMENT



HEART ATTACK ASSESSMENT



PERSONALIZED AI ALGORITHMS



HeartBeam

** FDA cleared for arrhythmia assessment only. Heart attack detection, AI algorithm, 12-Lead patch and HeartBeam Remote products not cleared by FDA and not available for sale in the United States or other geographies.*

Heart Attack Detection: Significant Milestones Achieved

Heart Attack Assessment: Regulatory Roadmap

Accelerating the Path to FDA Clearance

Positive Pilot Study Data	Alignment with FDA on 510(k) Pathway	Alignment with FDA on U.S. Pivotal Study Design	Commence U.S. Pivotal Study	U.S. Pivotal Study Enrollment Complete	FDA Clearance
COMPLETED ALIGN-ACS	**COMPLETED**	**EXPECTED** Q4 2026	**PLANNED** Q1 2027	**TARGET** MID-2027	CONTINUED DISCUSSIONS WITH FDA
Positive ALIGN-ACS pilot results presented at TCT 2026.	Alignment with the FDA on a 510(k) pathway for heart attack assessment, which further shortens the path to indication expansion.	Alignment with FDA on the multicenter U.S. Pivotal Study design, including endpoints and number of patients, expected in Q4 2026.	Patient enrollment anticipated in Q1 2027, intended to support a future FDA submission for heart attack assessment.	Completion of pivotal study enrollment targeted around mid-2027.	Leveraging Breakthrough Device Designation, TAP pilot, and ongoing discussions with FDA to accelerate path to FDA Clearance.

ACCELERATORS:


Breakthrough Device Designation
Granted Oct 2026 in 30 days: prioritized FDA review and interaction

TAP Pilot Acceptance
Accepted Oct 2026: dedicated FDA advisors with decades of industry experience; early payer and CMS engagement

Timeframes are management targets and forward-looking; there is no assurance of FDA authorization. TAP participation does not change regulatory requirements. HeartBeam System is FDA-cleared for arrhythmia assessment only. Use for heart attack assessment is investigational and not cleared by FDA.

ALIGN-ACS Pilot Study: Positive Results Presented at TCT 2026

Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG



132 patients · 2 ED sites in Belgrade, Serbia · 8 blinded cardiologists

0.73	**Our HeartBeam 3D 3-lead and the 12-lead showed same Area Under the Curve (AUC), implying identical information content**
100%	All study patients were able to successfully obtain 3D 3-lead ECG recordings
82.9%	STEMI sensitivity with HeartBeam vs. 83.8% for standard 12-lead ECG
0.73	Reader agreement (Fleiss' kappa) with CDS-assisted HeartBeam ECGs vs. 0.54 for 12-lead

Results from the ALIGN-ACS pilot study are intended to inform the design of a U.S. pivotal study planned to commence in the first quarter of 2027

Heart attack assessment is currently investigational and not an FDA-cleared indication for HeartBeam System.

Expanding Body of Clinical Evidence for Heart Attack Assessment

600+

patients enrolled across heart attack assessment studies ahead of the planned U.S. pivotal study

ALIGN-ACS + HEADSTART-ACS

ALIGN-ACS Pilot Study · Completed

132 patients across two emergency departments in Belgrade, Serbia. Positive results presented at TCT 2026.

HEADSTART-ACS · Enrollment complete; data analysis underway

486 patients at Harapan Kita National Cardiovascular Center, Jakarta. Enrolled ahead of schedule; results expected at a 2027 cardiology conference.

ALIGN-ACS II U.S. Pivotal Study

U.S. pivotal study, planned to begin in Q1 2027, intended to support an FDA submission for heart attack assessment.

EXIT-CVD · HEART-CHECK

HeartBeam to lead HEART-CHECK as part of consortium funded by EU IHI[1], alongside Philips, Medtronic, GE Healthcare and other global healthcare leaders.

[1] European Union Innovative Health Initiative.

HeartBeam System use in these studies is investigational. HeartBeam System is not CE marked and will be evaluated in HEART-CHECK for investigational purposes only. Not cleared by FDA for heart attack assessment. Timeframes are management targets and forward-looking.

Payment Pathways Evolving for Novel Cardiac Technologies

Building the real-world evidence and data collection we need to support our reimbursement strategy

1

Direct access to CMS and payors

TAP Pilot acceptance connects us with CMS, payors and provider organizations early, as we build real-world evidence and assess coding, coverage and payment pathways.

2

New and existing CPT codes

New CPT codes are emerging, a strong indicator of the clinical interest in algorithm-assisted ECG analysis.

3

Building supporting data for symptom-to-door time

Working with the FDA and CMS to define endpoints for a U.S. study supporting reimbursement for a heart attack assessment indication.

TAP participation does not guarantee FDA authorization or coverage. HeartBeam System is FDA-cleared for arrhythmia assessment only. Use for heart attack assessment is investigational and not cleared by FDA.

AI Program: Building on the 3D ECG Platform

Encouraging internal results; first peer-reviewed manuscript accepted

AI DATASETS

168,000+ ECGs for heart attack training

2,100+ HeartBeam device recordings for testing

HEART ATTACK ASSESSMENT

Arrhythmia AI model developed; current focus is heart attack assessment. In internal and initial analyses of HeartBeam recordings, the AI identified more heart attacks than physicians reading the same recordings.

Sensitivity: All heart attacks +12 pts



Sensitivity: Non-ST-elevation +19 pts



PUBLICATIONS

Atrial flutter AI algorithm

EHRA 2026 abstract (EP Europace); manuscript accepted, Canadian Journal of Cardiology.

97% accuracy vs. EP study (600 recordings, 12-lead ECGs).

COLLABORATIONS

Mount Sinai and University Hospital Basel

Expanding collaboration on AI applications with leading medical institutions.

HeartBeam AI is investigational for both arrhythmia and heart attack assessment and not FDA-cleared; HeartBeam System is FDA-cleared for arrhythmia manual assessment only.

Financials

Capital Efficiency Through Focused Path to Heart Attack Detection

$3.5M

Total operating expenses, Q3 2026

▼ 32% vs. Q2 2026
▼ 35% vs. Q3 2025

$2.6M

Net cash used in operating activities, Q3 2026


▼ 23% vs. Q2 2026
▼ 18% vs. Q3 2025

$10.1M


Pro forma cash and cash equivalents

$6.1M at 9/30/26 + ~$4.0M raised via ATM in Q4

Total operating expenses by quarter ($M)



Net cash used in operating activities by quarter ($M)



- Variable cost structure allowed Q3 cash outflow to come in significantly below expectations
- Pro forma cash extends the cash runway in line with the achievement of key milestones
- Baseline Q4 2026 net cash used in operations expected to be below $2.5M; accelerated U.S. Pivotal Study timing would add to Q4 spend
- Full-year 2026 net cash used in operations expected to be between $12.0M - $12.5M

Net cash used in operating activities = net loss less non-cash items and timing differences; Q3 2026 includes $0.4M of net settlement proceeds. Pro forma cash is unaudited, not a GAAP measure, and reflects approximately $4.0M raised under the ATM in Q4 2026. Refer to the Form 10-Q for the quarter ended September 30, 2026.

Third Quarter and Year-to-Date Results

	QUARTER ENDED			NINE MONTHS ENDED	
$ in thousands	Sep 30, 2026[i]	Jun 30, 2026	Sep 30, 2025	Sep 30, 2026[i]	Sep 30, 2025
Selling, general & administrative	1,339	2,764	2,012	6,449	5,733
Research & development	2,118	2,328	3,278	6,816	10,096
Total operating expenses	**3,457**	**5,092**	**5,290**	**13,265**	**15,829**
Other income, net[iv]	447	53	35	516	116
Net loss	**(3,010)**	**(5,039)**	**(5,255)**	**(12,749)**	**(15,713)**
Net loss per share	(0.05)	(0.10)	(0.15)	(0.25)	(0.48)
Less: non-cash items and timing differences	422	1,697	2,095	3,209	4,631
Net cash used in operating activities[ii]	**(2,588)**	**(3,342)**	**(3,160)**	**(9,540)**	**(11,082)**
Cash and equivalents, period end[iii]	6,122	8,779	1,856	6,122	1,856

i. Refer to the Form 10-Q for the quarter ended September 30, 2026.
ii. Calculated as net loss less non-cash items such as stock-based compensation and timing differences; quarterly figures derived from year-to-date cash flow statements.
iii. Includes restricted cash of $57K at September 30, 2026 and $56K at September 30, 2025.
iv. Q3 2026 includes $384K of net proceeds from a settlement agreement.

Summary: Key Takeaways

Heart Attack Detection is our top strategic priority

A massive opportunity within a $40B cardiac platform market, and we have the product, IP, and team to pursue it

SIGNIFICANT PROGRESS MADE

Recent milestones are the evidence

Breakthrough Device Designation, TAP Pilot acceptance, positive ALIGN-ACS pilot data and alignment with FDA on a 510(k) pathway

PATH TO PAYMENT

Payment pathways evolving

Direct access to CMS and payors; Building the real-world evidence and data collection we need to support our reimbursement strategy for heart attack assessment

EXECUTION PLAY

Development substantially complete

Hardware and software development are substantially complete; FDA Clearance and commercialization are the key areas within which to execute

HeartBeam System is FDA-cleared for arrhythmia assessment only. Heart attack detection and AI algorithm are investigational, not cleared by FDA and not available for sale in the United States or other geographies.

HeartBeam

NASDAQ: BEAT

Redefining Cardiac Care

Anytime, Anywhere.

Company

Tim Cruickshank
CFO
HeartBeam, Inc.
ir@heartbeam.com
www.heartbeam.com

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Q&A

HeartBeam System is FDA-cleared for arrhythmia assessment only. Heart attack detection and AI algorithm are investigational, not cleared by FDA and not available for sale in the United States or other geographies.

MKT-180 v1